Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OliGRAIL: RLT + Immunotherapy in Oligometastatic NSCLC
NCT06840782Phase 3Recruiting
- Sponsor
- Gustave Roussy
- Start
- Sep 2025
- Primary completion
- Feb 2030
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Gustave Roussy. Primary endpoint: Overall Survival up to 2 years. Started Sep 2025; status: recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06840782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06840782.